PI3K-δ inhibition would be expected to inhibit GC-insensitive responses such as mast cell degranulation and B-cell IgE production, as well as blocking the effects of IL-17, which is implicated in steroid-insensitive severe asthma. The gene discussed is IL17A; the disease is asthma.